Sugi Predict

Sugi Predict / Compounds / SCHEMBL11245903

SCHEMBL11245903

SCHEMBL11245903

CCCOc1ccncc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 5/20 0.64
▸ CYP3A4 P08684 3/20 0.64
▸ NPC1 O15118 5/20 0.61
▸ SMN1; SMN2 Q16637 5/20 0.61
▸ RAB9A P51151 3/20 0.61
▸ HSD17B10 Q99714 3/20 0.61
▸ HPGD P15428 2/20 0.61
▸ KDM4E B2RXH2 2/20 0.61
▸ ALDH1A1 P00352 2/20 0.61
▸ S1PR1 P21453 1/20 0.54
▸ S1PR3 Q99500 1/20 0.54
▸ MAPT P10636 3/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ LMNA P02545 6/20 0.51
▸ TSHR P16473 1/20 0.51
▸ LTA4H P09960 2/20 0.50
▸ CYP2C9 P11712 3/20 0.49
▸ CYP2C19 P33261 3/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ NFKB1 P19838 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylamine SCHEMBL27593589 0.94 CYP2D6 (0.58) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A
SCHEMBL7947076 0.88 CYP2D6 (0.81) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A
SCHEMBL2274461 0.87 CYP3A4 (0.51) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A
SCHEMBL22145062 0.86 CYP2D6 (0.71) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A
SCHEMBL525095 0.85 CYP2D6 (0.56) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A
SCHEMBL1573619 0.85 CYP2D6 (0.69) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A
SCHEMBL1996527 0.85 CYP2D6 (0.69) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A
SCHEMBL1874710 0.85 CYP2D6 (0.69) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A
SCHEMBL4887124 0.85 CYP2D6 (0.69) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A
SCHEMBL12743776 0.82 CYP2D6 (0.59) CYP2D6CYP3A4NPC1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106046888-A Adhesive for impeller locking devices and preparation method thereof 保定亿嘉特种陶瓷制造有限公司 2016-10-26 — — CN claimed
CN-102924445-A PIM kinase inhibitor, preparation method thereof, and application thereof in pharmacy SHANGHAI JIKAI MEDICAL TECHNOLOGY CO LTD 2013-02-13 — — CN claimed
CN-101993413-B Method for preparing 4-pyridine propyl alcohol SINOCHEM CORP 2012-12-12 — — CN claimed
CN-101993413-A Method for preparing 4-pyridine propyl alcohol SINOCHEM CORP 2011-03-30 — — CN claimed
CN-101572188-B Dye-sensitized solar cell electrolyte additive and synthetic method and application thereof CHINESE ACAD INST CHEMISTRY 2011-02-02 — — CN claimed
CN-101572188-A Dye-sensitized solar cell electrolyte additive and synthetic method and application thereof CHINESE ACAD INST CHEMISTRY (CN) 2009-11-04 — — CN claimed
US-4192949-A FROM CORRESPONDING PHENOLS BY ETHERIFICATION WITH DIALKYL CARBONATE IN TERTIARY AMINE OR PHOSPHINE BASF AKTIENGESELLSCHAFT (DE) 1980-03-11 — — US claimed
EP-4318630-B1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY ASAHI CHEMICAL IND (JP) 2025-10-22 — — EP disclosed
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-01-14 — — US disclosed
EP-4415105-A2 NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE Asahi Kasei Kabushiki Kaisha (JP) 2024-08-14 — — EP disclosed
US-20240178452-A1 Nonaqueous Electrolyte Solution and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-05-30 — — US disclosed
EP-4318630-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY Asahi Kasei Kabushiki Kaisha (JP) 2024-02-07 — — EP disclosed
CN-117223143-A Nonaqueous electrolyte and nonaqueous secondary battery 旭化成株式会社 2023-12-12 — — CN disclosed
CN-1206407-A Substituted vinylpyridine derivatives and medicaments containing them SS PHARMACEUTICAL CO (JP) 1999-01-27 — — CN disclosed
CN-1205694-A Quinazoline derivatives ZENECA LTD (GB) 1999-01-20 — — CN disclosed
EP-0011188-B1 PROCESS FOR PREPARING CYANOARYL ETHERS AND CYANOARYL THIOETHERS BASF Aktiengesellschaft (DE) 1982-04-28 — — EP disclosed
EP-0000162-B1 Method for preparing aralkyl and alkyl phenol ethers BASF Aktiengesellschaft (DE) 1980-08-20 — — EP disclosed
EP-0011188-A2 Process for preparing cyanoaryl ethers and cyanoaryl thioethers BASF Aktiengesellschaft (DE) 1980-05-28 — — EP disclosed
US-4192949-A FROM CORRESPONDING PHENOLS BY ETHERIFICATION WITH DIALKYL CARBONATE IN TERTIARY AMINE OR PHOSPHINE BASF AKTIENGESELLSCHAFT (DE) 1980-03-11 — — US disclosed
EP-0000162-A1 Method for preparing aralkyl and alkyl phenol ethers BASF Aktiengesellschaft (DE) 1979-01-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte CLK2, TYK2, CLK3 CYP2D6 4271/4885CYP3A4 3798/4885NPC1 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.